Navigation Links
BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
Date:9/3/2009

LYNBROOK, N.Y., Sept. 3 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products today announced results of the pivotal CORD I Phase III clinical trial of XIAFLEX(TM) (collagenase clostridium histolyticum), a novel, first-in-class biologic for the nonsurgical treatment of Dupuytren's disease, was published in today's edition of the New England Journal of Medicine (N. Engl. J. Med. 2009;361:968-79.). The article, entitled "Injectable Collagenase Clostridium Histolyticum for Dupuytren's Contracture" describes the positive results observed in a Phase III trial conducted by BioSpecific's licensee Auxilium Pharmaceuticals, Inc. Dupuytren's disease is a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers. The first Phase III study of XIAFLEX in Dupuytren's disease was sponsored and monitored by BioSpecifics, with follow-up and data analysis conducted by Auxilium.

"We are very pleased that the results of the successful CORD 1 study were published in this premier medical journal," stated Thomas L. Wegman, President of BioSpecifics. "The details of the study provided in the article further support our view and enthusiasm for the potential benefits of XIAFLEX as a treatment for Dupuytren's disease, and we look forward to the upcoming review by the Arthritis Advisory Committee to the Food and Drug Administration on September 16."

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for three clinical indications: Dupuytren's disease; Peyronie's disease; and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. has announced the acceptance of the Biologic License Application (BLA) and Priority Review by the U.S. Food and Drug Administration for injectable collagenase XIAFLEX(TM) in the treatment of Dupuytren's disease. Pfizer, Inc. is responsible for marketing XIAFLEX(TM) product in Europe.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
2. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
3. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
4. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
5. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
6. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
7. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
8. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
9. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
10. Senesco Technologies Initiates Preclinical Studies for Cancer Target
11. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Los innovadores de COMBO[TM], ... introduce catéteres para la intervención de extremidades inferiores ... global especializada en el suministro de soluciones vasculares ... incluyendo productos para tratar la enfermedad arterial periférica. ... los dispositivos de primera entrada de la compañía ...
(Date:5/24/2016)... , May 24, 2016 ... elkaar verbindt, zodat zij collectief patiënten kunnen behandelen, hun ... is het idee achter de nieuwe en revolutionaire MDLinking ... van de Nederlandse vaatchirurg dr. Hans Flu en oncologisch ... app, die inmiddels beschikbaar is, wordt op dinsdag 24 ...
(Date:5/23/2016)... York , May 23, 2016 ... report titled, " Exocrine Pancreatic Insufficiency Market - Global ... - 2023 ." According to the report, the exocrine ... CAGR of 8.3% from 2015 to 2023 to reach ... (EPI) is a condition characterized by the deficiency of ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... The ... Drug Development through Molecular Imaging.” The focus of ADDMI-IG will be geared towards ... and development pipeline issues. Through ADDMI-IG WMIS will provide a platform for productive ...
(Date:5/25/2016)... Miami, FL (PRWEB) , ... May 25, 2016 , ... ... deep dive into the unique integrative medical wellness offerings of Europe, a continent that ... in Tyrol, Austria will hear from numerous pioneers in medical wellness, including Henri Chenot, ...
(Date:5/25/2016)... ... ... Casa Velas, an adults-only boutique hotel in Puerto Vallarta, Mexico, introduces a ... wellness suites . The two 1,350 sq. ft. suites which debuted in late 2015 ... amenities, from a custom soap selection and in-suite exercise kit to a personal wellness ...
(Date:5/25/2016)... ... May 25, 2016 , ... America Walks , a ... M.S.L., M.S.P.A., of the University of Pittsburgh Graduate School of Public Health , ... Ms. Reichbaum and 24 other advocates from around the country to participate in a ...
(Date:5/25/2016)... ... May 25, 2016 , ... "FCPX LUT Intense allows users to ... said Christina Austin - CEO of Pixel Film Studios. , With the FCPX ... add stylish color grades to their footage. A LUT is a Lookup Table that ...
Breaking Medicine News(10 mins):